Form 4: Acurx Pharmaceuticals Director James J. Donohue Acquires Shares and Warrants in Direct Offering

Director James J. Donohue increased his holdings in Acurx Pharmaceuticals through a direct stock offering and private placement of warrants.

Summary

• On January 6, 2025, James J. Donohue, a director of Acurx Pharmaceuticals, acquired 9,852 shares of common stock at a price of $1.015 per share.
• This acquisition was part of a registered direct offering by Acurx Pharmaceuticals.
• In addition to the stock purchase, Donohue also acquired warrants for 9,852 shares of common stock at an exercise price of $0.90 per share, expiring on January 7, 2030.
• These warrants were obtained through a concurrent private placement in connection with the direct offering.
• Following these transactions, Donohue's direct ownership includes 22,352 shares of common stock and 9,852 warrants.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider trading activity. The director's purchase could be seen as a positive signal, but it's not overwhelmingly so.

Positives

• The director's purchase of shares and warrants may signal confidence in the company's future prospects.

Industry Context

This transaction is a routine disclosure of insider activity, common in publicly traded companies. It provides transparency into the actions of company insiders.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies, ensuring transparency of insider transactions.
• Comparable companies like BioCryst Pharmaceuticals or Ligand Pharmaceuticals also have frequent Form 4 filings reflecting insider activity.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company insider.

Key Dates